These questions were first raised five years ago' and continue to trouble those involved with diabetes. The issue is difficult to resolve because the suspected adverse effects of human insulin-that is, reduced awareness of hypoglycaemia and increased rate of severe episodes -are inextricably woven into the fabric of insulin treatment. Despite many patients' claims the ability to estimate the prevailing blood glucose concentration is notoriously poor2; for example, even educated and motivated patients who took part in a recent study of hypoglycaemia wrongly judged themselves to be hypoglycaemic in a quarter of episodes.3 Perception of hypoglycaemia can be dulled by many factors, including alcohol and various drugs. Moreover, for reasons which remain obscure, many patients with longstanding diabetes lose awareness of the onset of hypoglycaemia and may rapidly develop neuroglycopenic features (for example, confusion, aggression, and coma) before any recognisable sympathetically mediated symptoms such as sweating and tremor. This occurs irrespective of the insulin species used and was well recognised long before the advent of human insulin.4 I Hypoglycaemia is an inevitable consequence of the narrow therapeutic ratio of insulin and is a common complication of treatment of diabetes: each year one in seven insulin dependent diabetic patients will have a hypoglycaemic episode severe enough to cause unconsciousness or require help from others. A specific effect of human insulin is all the harder to detect against this noisy background because its introduction during the 1980s generally coincided with greater efforts to tighten glycaemic control by intensifying insulin treatment, which itself may make hypoglycaemia more frequent.6 This important confounding factor, also not related to insulin species, is highlighted by the 68% increase in the frequency of severe hypoglycaemia observed in diabetic children in Bern between 1984 and 1988 . This rise paralleled the effect ofinsulin species because individual symptomatic increasing use of human insulin but occurred equally and neuroendocrine responses to hypoglycaemia are so in patients receiving human or animal insulins; variable; repeated studies would compress the error interestingly,.a similar rise in the background rate of bars and placate the statisticians but would be unhypoglycaemia could explain most of the excess acceptable to subjects and ethics committees alike. The episodes attributed to the use of human insulin in hypothesis that human insulin increases the frequency adults in the same region.8 of severe hypoglycaemic episodes can be tested only in To find a solution to this vexed issue and to limit the field studies, and this is probably the only setting medical and social damage in the interim, several which will carry credibility for diabetic patients. All theoretical and practical questions must be addressed. the subjects from our own laboratory study,"' which failed to show any significant differences between human and porcine insulins, remain convinced that Two separate hypotheses must be tested-namely, period did not disclose any significant differences between that the use of human insulin (a) impairs the perception them in the endocrine, symptomatic, or psychomotor of hypoglycaemic symptoms and (b) increases the changes during hypoglycaemia. The full paper is awaited frequency of severe hypoglycaemic episodes. The first with interest. is scientifically interesting and may clarify the direct effects of insulin on the brain, but it is the second which is of vital importance to diabetic people. Any What should be done in the interim? future studies must aim specifically at testing one or In our opinion the balance of available evidence does both of these hypotheses and must be powerful enough not suggest that human insulin specifically impairs to do this; neglect of this basic principle has invalidated perception of hypoglycaemic symptoms or that its use several previous studies.
predisposes to severe hypoglycaemia. Irrespective of The literature includes anecdotes and case reports, whether we are right or wrong, we have a duty of care laboratory studies, and retrospective and prospective to help our diabetic patients to live with a difficult and surveys, which have been performed in diabetic or demanding disease. The wishes of the patient must non-diabetic subjects with widely variable selection therefore be respected. Accordingly, we have no criteria. The enthusiasm with which the various hesitation in transferring patients back to animal groups have attacked their opponents' work (for insulins if they so wish, although all the usual preexample, references 16 and 17) forces us to conclude cipitants of hypoglycaemia (especially mismatching of that none of the published studies-including our insulin, food and exercise, and alcohol and drugs) must own'5-can be regarded as definitive. None the less, also be sought and excluded if possible. Hypoglycaemia previous work has been useful in identifying important is the main fear of most insulin dependent diabetic pitfalls which must be avoided in future.
people and often overshadows the threat of long term Because of general awareness of the debate and complications; if any good emerges from the current (regrettably) the possible motive of compensation unpleasantness it will be to remind everyone that claims insulin species can now be compared only under diabetes is an important medical and social problem at least single blind conditions. "One off' laboratory and to emphasise that doctors must take hypoglycaemia studies may not be powerful enough to detect a genuine seriously.
Diabetes is a complicated disease which demands close cooperation between the patient and the diabetes care team and, as such, is totally unsuited to the practice of defensive medicine. It is therefore unfortunate that the human insulin issue may result in litigation, perhaps against those who prescribe insulin as well as the drug companies which manufacture it. This is another compelling reason for trying to resolve the scientific debate as rapidly as possible.
Future strategy
Both sides of the human insulin debate were recently represented at a well attended symposium in Liverpool.2" Some rapprochement occurred in that previous studies and their limitations were discussed, generally in a constructive spirit. A series of suggestions emerged, which seem sensible guidelines for the present (box).
Suggested strategy for managing diabetic patients with insulin
(1) Patients who are satisfactorily treated with animal insulin should not be transferred routinely to human insulin. If transfer is indicated on medical grounds (for example, hypersensitivity to animal insulins) the doctor should discuss this fully with the patient and monitor the change over carefully. It is not acceptable for patients to be transferred to human insulin by pharmacists (2) Patients receiving human insulin should be transferred back to animal insulin if they so wish (3) Animal insulin preparations must therefore remain available, they should include cartridges for the pen injection devices which are increasingly popular with patients (only human insulin cartridges are available for the most widely used devices) (4) Adequately designed studies should be performed as a matter of urgency to determine conclusively whether human insulin has specific adverse effects ANY QUESTIONS Is there any evidence thatpierced ears are a source ofinfection, and are there any European Community regulations governing the sale ofearrings for pierced ears?
There are several aspects to this inquiry. Ear piercing does carry a risk of infection. In 1983 European Community (EC) directives were issued under the Local Government Miscellaneous Provisions Act 1982, which required the registration of people undertaking ear piercing in England and Wales. The directive specified that there should be no risk of transmitted infection. Manufacturers redesigned their ear piercing equipment, and several "gun" systems are now available which use presterilised ear studs and back clasps. In 1987 the Department of Health and Social Security issued a guidance for piercers, which recommended the use of these "gun" systems. Interestingly, there seem to be no EC regulations on this matter.
Once an epithelialised sinus has been created by ear piercing it is unlikely to be broached by micro-organisms, but inflammatory changes around the piercing site are commonly observed. These changes are usually traumatic in origin and may be caused by the person fiddling with the earring or wearing excessively heavy earrings. Sometimes inflammation may arise from wearing earrings in windy conditions or during vigorous exercise. Such inflammation may be accompanied by swelling of the sebaceous glands in the ear lobe. Unless this traumatic inflammation is complicated by infection treatment is not required and the problem usually settles with rest.
Contact dermatitis caused by earrings is also common. There is a significant correlation between ear piercing and the development of nickel sensitivity.' Piercing studs are usually gold plated stainless steel, and although the steel does contain nickel it is usually well complexed and relatively non-allergic. EC regulations do exist on this matter and specify a minimum of a 124m plating of gold. The act of piercing is unlikely to be responsible for the nickel sensitivity, which probably arises from subsequent exposure to earrings containing nickel. Once eczema occurs it can become infected. In my experience patients suffering this are often persistent carriers of staphylococci. Although the infected eczema will usually respond rapidly to a steroid-antibiotic combination, the problem will recur unless the wearing of earrings containing nickel is avoided.
Other recognised complications of ear piercing include the development of dumb bell keloids and granuloma, but such complications are not generally associated with infection. -R D ALDRIDGE, senior lecturer and honorary consultant dermatologist, Edinburgh
